Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Molybdate-anion transporter (SLC61A1, also known as MFSD5) is a multi-pass membrane protein that functions as a high-affinity transporter for molybdate ions, a biologically essential trace element involved in the function of various enzymes. It belongs to the major facilitator superfamily (MFS) of transporters and is predicted to mediate the uptake of molybdate across cellular membranes, particularly in neuronal plasma membranes[1][4][6][8]. While it is a plausible therapeutic target due to its transporter function, there are no established interacting drugs or clear roles in major human diseases. The gene is located in the plasma membrane and is considered an atypical member of the solute carrier transporter family, specifically designated SLC61A1[1][2][6][8]. The precise physiological and pathological roles remain under investigation, but associated studies suggest a potential link to extratemporal epilepsy[8]. No current therapy targets this transporter, and no safety or biomarker issues are defined.
Not established for drug action; mediates high-affinity intracellular uptake of molybdate ions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Molybdate-anion transporter (SLC61A1).